TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.

Also called NCT06802081

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 100 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06802081
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06802081. Randomized; triple masking; primary purpose treatment. Start 2025-04-08 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
Acronym
TIRO-AF
Condition
Obesity
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Placebo
Lead sponsor
The Cleveland Clinic (class: other)

Record details

Record id
cardio:ct-nct06802081
Content hash
2cd7a4b5fceb76ff8a6d5374d140b63ede65203226cab2859c41e6a2d07a50c1